Half Year Report

Summary by AI BETAClose X

CRISM Therapeutics Corporation announced its unaudited half-year results for the six months ended June 30, 2025, reporting a loss for the period of £930,000. Administration expenses totaled £905,000, including £357,000 in research and development. As of June 30, 2025, the company's cash reserves stood at £349,000. Subsequent to the period, in July 2025, CRISM raised £874,021 through a placing and retail offer. The company was also awarded an Innovate UK Launchpad grant of £96,106. Net cash at September 12, 2025, was £906,864. The company allotted 6,666,668 new ordinary shares on July 3, 2025, and raised gross proceeds of £54,021 via a subscription of 450,176 new ordinary shares on July 2, 2025.

Disclaimer*

UK 100

Latest directors dealings